Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric ulcerative colitis study of ustekinumab induction and maintenance
jRCT2041200098Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of ustekinumab in autoimmune colitis (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Clinical remission at induction Week 8, Adverse events and 7 more. Started Oct 2021; status: completed.
02
Drugs
ustekinumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2041200098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041200098.